Author

A M Navar

Institution: The University of Texas Southwestern Medical Center

Observed institution: The University of Texas Southwestern Medical Center

OpenAlex ID: A5159610566

Efficacy of enlicitide across ESC cardiovascular risk categories in two CORALreef phase 3 trials

2026 · E S G Stroes, C M Ballantyne, et al. · European Heart Journal

Efficacy of enlicitide, an oral PCSK9 inhibitor, across baseline Lp(a) strata in an analysis of two phase 3 trials

2026 · P Corral, J A Parham, et al. · European Heart Journal

Real world evaluation of lipoprotein (a) testing and impact on LDL-C management in atherosclerotic cardiovascular disease patients: findings from the CVMOBIUS2 registry

2026 · N P Shah, P Shrader, et al. · European Heart Journal

Works count: 3

Citation count:

H-index:

I10-index: